Information for students, faculty and staff regarding COVID-19. (Updated: 23 November 2020)

Svenska
Umeå University
printicon
Staff photo Marcus Schmitt-Egenolf

Marcus Schmitt-Egenolf

• Real world evidence, Preventive medicine, Ethics, Psoriasis, Melanoma, Genodermatoses

• Coordinator, educationally awarded teachers network

• Head of the Swedish psoriasis register PsoReg

Contact

E-mail
marcus.schmitt-egenolf@umu.se
Phone
+46 90 786 54 72

Works at

Affiliation
Professor, senior consultant (attending) physician at Department of Public Health and Clinical Medicine Units: Section of Medicine, Dermatology and Venereology
Location
1A, målpunkt B41, enheten för medicin, Norrlands Universitetssjukhus Umeå universitet, by1a, B41, NUS, 901 85 Umeå

Marcus main interests are Real world evidence, Preventive medicine, Ethics, Psoriasis, Melanoma and Genodermatoses. He initiated the Swedish national psoriasis registry www.PsoReg.se and co-founded the international PsoNet register. Marcus is a distinguished teacher and co-coordinates the educationally awarded teachers network @ Umeå university. Marcus is a scientific advisor to several public authorities and other decision-makers and participates in national and international expert groups.

Bio:
Marcus studied medicine in Frankfurt, Vienna, Kiel & Edmonton. During his studies, he started his psoriasis research with a thesis on the immunogenetics of psoriasis under the guidance of Enno Christophers and Wolfram Sterry. The German research council (DFG) funded his postdoc at the laboratory of Georg Stingl in Vienna from 1993-95. Thereafter, he completed his specialist training at the Charité in Berlin. He was appointed associate professor of dermatology at the NTNU in Trondheim, Norway in 2000. Since 2002 he has been working at Umeå university, where he was appointed head of the division of dermatovenereology in 2012, full professor and distinguished teacher in 2014. 

• Affiliated researcher
    -Centre for Pharmacoepidemiology, Karolinska Institutet 
      www.safetyness.org   
    -Arctic Research Centre Arcum
• Associate Editor, British Journal of Dermatology
• Editorial board:
    -BMC Dermatology
    -Clinical Drug Investigation
    -Journal of Clinical Medicine

Senior advisor:
• Swedish Board of Health and Welfare (SoS)
• Swedish Agency for Health Technology Assessment (SBU)
• Medical Products Agency (MPA)
• Swedish Dental and Pharmaceutical Benefits Agency (TLV)
• Swedish psoriasis patient organisation (PSO)

Coordinator:
• Master thesis (30 ECTS), medicine program, Umeå univ.
• Psoriasis research, the medical biobank Umeå  

• Pubmed
• ResearchGate
• Publons
• LinkedIn

2020
Anti-TNF treatment during pregnancy and birth outcomes: Apopulation-based study from Denmark, Finland, and Sweden
Pharmacoepidemiology and Drug Safety, Vol. 29, (3) : 316-327
Broms, Gabriella; Kieler, Helle; Ekbom, Anders; et al.
2020
Paediatric infections in the first 3 years of life after maternal anti-TNF treatment during pregnancy
Alimentary Pharmacology and Therapeutics
Bröms, Gabriella; Kieler, Helle; Ekbom, Anders; et al.
2020
Association of Skin Psoriasis and Somatic Comorbidity With the Development of Psychiatric Illness in a Nationwide Swedish Study
JAMA dermatology, American Medical Association 2020, Vol. 156, (7) : 795-804
Geale, Kirk; Henriksson, Martin; Jokinen, Jussi; et al.
2020
Complete skin clearance and Psoriasis Area and Severity Index response rates in clinical practice: predictors, health-related quality of life improvements and implications for treatment goals
British Journal of Dermatology, Wiley-Blackwell 2020, Vol. 182, (4) : 965-973
Norlin, J. M.; Nilsson, K.; Persson, U.; et al.
2020
Complete skin clearance and beyond
British Journal of Dermatology
Schmitt-Egenolf, Marcus
2020
Health Related Quality of Life in Melanoma Patients: characterization of a Swedish cohort
British Journal of Dermatology, Wiley-Blackwell 2020, Vol. 182, (2) : 506-508
Tufvesson Stiller, Helena; Mikiver, R.; Uppugunduri, S.; et al.
2019
Infant Infections after Maternal Anti-TNF Treatment in Pregnancy
Pharmacoepidemiology and Drug Safety, Wiley 2019, Vol. 28 : 10-10
Broms, Gabriella; Kieler, Helle; Ekbom, Anders; et al.
2019
Case validation of cutaneous lymphoma to minimize protopathic bias
Pharmacoepidemiology and Drug Safety, Wiley 2019, Vol. 28, (S2) : 315-315
Gutierrez, Lia; Booth, Helen; Dedman, Daniel; et al.
2018
Tnf inhibitor treatment during pregnancy and risk of preterm birth
Pharmacoepidemiology and Drug Safety, John Wiley & Sons 2018, Vol. 27 : 30-31
Bröms, Gabriella; Kieler, Helle; Ekbom, Anders; et al.
2018
Sustained Psoriasis Area and Severity Index, DermatologyLife Quality Index and EuroQol-5D response of biologicaltreatment in psoriasis: 10 years of real-world data in theSwedish National Psoriasis Register
British Journal of Dermatology, Hoboken: John Wiley & Sons 2018, Vol. 178, (1) : 245-252
Hjalte, F.; Steen Carlsson, K.; Schmitt-Egenolf, Marcus
2018
What can we learn from 'dropouts' in clinical trials?
British Journal of Dermatology, John Wiley & Sons 2018, Vol. 178, (2) : 318-319
Schmitt-Egenolf, Marcus
2017
Regional Differences in the Prescription of Biologics for Psoriasis in Sweden: a Register-Based Study of 4168 Patients
BioDrugs, Vol. 31, (1) : 75-82
Calara, Paul S; Althin, Rikard; Carlsson, Katarina Steen; et al.
2017
How is disease severity associated with quality of life in psoriasis patients?: Evidence from a longitudinal population-based study in Sweden
Health and Quality of Life Outcomes, Vol. 15, (1)
Geale, Kirk; Henriksson, Martin; Schmitt-Egenolf, Marcus
2017
Severity of psoriasis differs between men and women: a registry based study of the clinical outcome measure Psoriasis Area and Severity Index (PASI) in 5438 patients
American Journal of Clinical Dermatology, Vol. 18 : 583-590
Hägg, David; Sundström, Anders; Eriksson, Marie; et al.
2017
Real-world outcomes in 2,646 psoriasis patients: one in five has PASI ≥ 10 and/or DLQI ≥ 10 under ongoing systemic therapy
Journal of dermatological treatment (Print), Vol. 28, (6) : 500-504
Norlin, J. M.; Calara, P. S.; Persson, U.; et al.
2016
Healthcare Provider Type and Switch to Biologics in Psoriasis: Evidence from Real-World Practice
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, Vol. 30, (2) : 145-151
Calara, Paul S.; Norlin, Jenny M.; Althin, Rikard; et al.
2016
Evaluating equality in psoriasis healthcare: a cohort study of the impact of age on prescription biologics
British Journal of Dermatology, Vol. 174, (3) : 579-587
Gaele, Kirk; Henriksson, Martin; Schmitt-Egenolf, Marcus
2016
Psoriasis Patients New to Specialist Care in Sweden 2007-2009: A Two-Year Follow-Up of Treatment Allocation
Pharmacoepidemiology and Drug Safety, Wiley-Blackwell 2016, Vol. 25 : 4-5
Hägg, David; Eriksson, Marie; Schmitt-Egenolf, Marcus; et al.
2016
Periodontal Ehlers-Danlos Syndrome Is Caused by Mutations in C1R and C1S, which Encode Subcomponents C1r and C1s of Complement
American Journal of Human Genetics, Cell Press 2016, Vol. 99, (5) : 1005-1014
Kapferer-Seebacher, Ines; Pepin, Melanie; Werner, Roland; et al.
2016
Physical activity and lifestyle improvement in the management of psoriasis
British Journal of Dermatology, Vol. 175, (3) : 452-453
Schmitt-Egenolf, Marcus
2015
The Relationship Between Disease Severity and Quality of Life In Patients With Moderate to Severe Psoriasis
Value in Health, Vol. 18, (7) : A675-A675
Geale, Kirk; Henriksson, M.; Schmitt-Egenolf, Marcus
2015
Real-world outcome analysis of continuously and intermittently treated patients with moderate to severe psoriasis after switching to a biologic agent
Dermatology, S. Karger 2015, Vol. 230, (4) : 347-353
Hjalte, Frida; Steen Carlsson, Katarina; Schmitt-Egenolf, Marcus
2015
Decision for biological treatment in real life is more strongly associated with the Psoriasis Area and Severity Index (PASI) than with the Dermatology Life Quality Index (DLQI)
Journal of the European Academy of Dermatology and Venereology, John Wiley & Sons 2015, Vol. 29, (3) : 452-456
Hägg, David; Sundström, A; Eriksson, Marie; et al.
2015
Register-Based Evaluation of Relative Effectiveness of New Therapies: Biologics Versus Conventional Agents in Treatment of Psoriasis in Sweden
BioDrugs, Vol. 29, (6) : 389-398
Norlin, Jenny M.; Steen Carlsson, Katarina; Persson, Ulf; et al.
2015
Resource use in patients with psoriasis after the introduction of biologics in Sweden
Acta Dermato-Venereologica, Vol. 95, (2) : 156-161
Norlin, Jenny M.; Steen Carlsson, Katarina; Persson, Ulf; et al.
2015
Hair shaft structures in EDAR induced ectodermal dysplasia
BMC Medical Genetics, BioMed Central 2015, Vol. 16
Stecksén-Blicks, Christina; Falk Kieri, Catharina; Schmitt-Egenolf, Marcus; et al.
2014
EDAR-induced hypohidrotic ectodermal dysplasia: a clinical study on signs and symptoms in individuals with a heterozygous c.1072C > T mutation
BMC Medical Genetics, BioMed Central 2014, Vol. 15 : 57-
Falk Kieri, Catarina; Bergendal, Birgitta; Lind, Lisbet K; et al.
2014
Health care delay in malignant melanoma: various pathways to diagnosis and treatment
Dermatology Research and Practice, Hindawi Publishing Corporation 2014 : 294287-
Hajdarevic, Senada; Hörnsten, Åsa; Sundbom, Elisabet; et al.
2014
Registerstudier mäter effektivitet av läkemedel i klinisk praxis: Exemplet PsoReg – omfördelning av systemisk terapi kan ge ökad effektivitet
Läkartidningen, Vol. 111, (24) : 1061-3
Norlin, Jenny; Schmitt-Egenolf, Marcus; Steen Carlsson, Katarina; et al.
2013
Coping styles in decision making among men and women diagnosed with malignant melanoma
Journal of Health Psychology, Sage Publications 2013, Vol. 18, (11) : 1445-1455
Hajdarevic, Senada; Schmitt-Egenolf, Marcus; Sundbom, Elisabet; et al.
2013
The higher proportion of men with psoriasis treated with biologics may be explained by more severe disease in men
PLoS ONE, Public library of science 2013, Vol. 8, (5) : e63619-
Hägg, David; Eriksson, Marie; Sundström, Anders; et al.
2012
Analysis of three outcome measures in moderate to severe psoriasis: a registry-based study of 2450 patients
British Journal of Dermatology, Wiley-Blackwell 2012, Vol. 166, (4) : 797-802
Norlin, Jenny M; Steen Carlsson, K; Persson, U; et al.
2012
Switch to biological agent in psoriasis significantly improved clinical and patient-reported outcomes in real-world practice
Dermatology, S. Karger 2012, Vol. 225, (4) : 326-332
Norlin, Jenny M; Steen Carlsson, Katarina; Persson, Ulf; et al.
2012
Challenges for synthesising data in a network of registries for systemic Psoriasis therapies
Dermatology, S. Karger 2012, Vol. 224, (3) : 236-243
Ormerod, AD; Augustin, M; Baker, C; et al.
2011
Malignant melanoma: gender patterns in care seeking for suspect marks
Journal of Clinical Nursing, Wiley-Blackwell 2011, Vol. 20, (17-18) : 2676-2684
Hajdarevic, Senada; Schmitt-Egenolf, Marcus; Brulin, Christine; et al.
2010
Patients' decision making in seeking care for suspected malignant melanoma
Journal of Nursing and Healthcare of Chronic Illness, Wiley-Blackwell 2010, Vol. 2, (2) : 164-173
Hajdarevic, Senada; Hörnsten, Åsa; Sundbom, Elisabet; et al.
2009
How dermatologists can evaluate systemic psoriasis treatments
Forum for nordic dermato-venereology, Vol. 14, (2) : 38-40
Schmitt-Egenolf, Marcus
2008
Switching biologicals: switching TNFalpha antagonists in psoriasis treatment
Dermatology, S. Karger 2008, Vol. 216, (4) : 281-282
Schmitt-Egenolf, Marcus
2007
PsoReg: the Swedish registry for systemic psoriasis treatment. The registry's design and objectives.
Dermatology, S. Karger 2007, Vol. 214, (2) : 112-117
Schmitt-Egenolf, Marcus
2006
EDAR mutation in autosomal dominant hypohidrotic ectodermal dysplasia in two Swedish families
BMC Medical Genetics, BioMed Central 2006, Vol. 7 : 80-
Lind, Lisbet K; Stecksén-Blicks, Christina; Lejon, Kristina; et al.
2006
Psoriasis therapy in real life: the need for registries
Dermatology, S. Karger 2006, Vol. 213, (4) : 327-330
Schmitt-Egenolf, Marcus
2004
Pso-Reg: the quality register for systemic psoriasis treatment
Forum for Nordic dermato-venereology, Nordic dermatological association 2004, Vol. 9, (4) : 94-97
Schmitt-Egenolf, Marcus
2003
Interleukin-10 promoter polymorphism IL10.G and familial early onset psoriasis
British Journal of Dermatology, John Wiley & Sons 2003, Vol. 149, (2) : 381-385
Hensen, P; Asadullah, K; Windemuth, C; et al.
2003
Association scan of the novel psoriasis susceptibility region on chromosome 19: evidence for both susceptible and protective loci
Experimental dermatology, John Wiley & Sons 2003, Vol. 12, (4) : 490-496
Hensen, P; Windemuth, C; Hüffmeier, U; et al.
2001
Comparative association analysis reveals that corneodesmosin is more closely associated with psoriasis than HLA-Cw*0602-B*5701 in German families
Tissue Antigens, John Wiley & Sons 2001, Vol. 57, (5) : 440-446
Schmitt-Egenolf, Marcus; Windemuth, C; Hennies, HC; et al.
2000
Genomewide scan in german families reveals evidence for a novel psoriasis-susceptibility locus on chromosome 19p13
American Journal of Human Genetics, Elsevier 2000, Vol. 67, (4) : 1020-1024
Lee, YA; Rüschendorf, F; Windemuth, C; et al.
2000
PERB11 (MIC): a polymorphic MHC gene is expressed in skin and single nucleotide polymorphisms are associated with psoriasis.
Clinical and Experimental Immunology, John Wiley & Sons 2000, Vol. 119, (3) : 553-558
Tay, GK; Hui, J; Gaudieri, S; et al.
1999
Promoter polymorphism at -238 of the tumor necrosis factor alpha gene is not associated with early onset psoriasis when tested by the transmission disequilibrium test
Journal of Investigative Dermatology, Nature Publishing Group 1999, Vol. 112, (4) : 513-514
Jacob, N; Rüschendorf, F; Schmitt-Egenolf, Marcus; et al.
1999
Survival, maturation, and function of CD11c- and CD11c+ peripheral blood dendritic cells are differentially regulated by cytokines
Journal of Immunology, American association of immunologists 1999, Vol. 163, (6) : 3250-3259
Kohrgruber, N; Halanek, N; Gröger, M; et al.
1997
Association between interleukin-1 receptor antagonist (IL-1ra) gene polymorphism and early and late-onset psoriasis
British Journal of Dermatology, John Wiley & Sons 1997, Vol. 136, (1) : 147-148
Tarlow, JK; Cork, MJ; Clay, FE; et al.
View publications in DiVA

Research projects

6 October 2010 until 31 May 2013
Melanoma, a new approach to decrease delay of diagnosis and treatment